Table 3.
Noteworthy differences in case reports
| ILD improved (N=5) | ILD induced or deteriorate (N=35) | p-Value | |
|---|---|---|---|
| Age | 67.4±3.56 years | 65.23±10.16 years | 0.642 |
| Gender (female) (number/ratio) | 1(25.71%) | 26(74.29) | 0.031 |
| History of RA | 5±3.56 years | 15±4.4 years | 0.000 |
| Used of MTX (number/ratio) | 3(60%) | 24(68.37%) | 1.00 |
| Onset of disease | 1 year | INF 2–3 wks after 2–3 doses | – |
| Using INF (number/ratio) | 5(100%) | 17(48.57%) | 0.053 |
| CCP or RF positive (number/ratio) | 4(80%) | 24(68.57%) | – |
Abbreviation: ILD, interstitial lung disease; RA, rheumatoid arthritis; MTX, methotrexate; INF, infliximab; CCP cyclic citrullinated peptides; RF, rheumatoid factor.